These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29796306)

  • 1. Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology.
    Zhu AZ
    Future Sci OA; 2018 Jun; 4(5):FSO306. PubMed ID: 29796306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
    Fleisher B; Brown AN; Ait-Oudhia S
    Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices.
    Bai JPF; Earp JC; Pillai VC
    AAPS J; 2019 Jun; 21(4):72. PubMed ID: 31161268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.
    Block M
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA).
    Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y
    Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical QSP application from the preclinical phase to enhance the probability of clinical success: Insights from case studies in oncology.
    Oishi M; Sayama H; Toshimoto K; Nakayama T; Nagasaka Y
    Drug Metab Pharmacokinet; 2024 Jun; 56():101020. PubMed ID: 38797089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational PK/PD modeling to increase probability of success in drug discovery and early development.
    Lavé T; Caruso A; Parrott N; Walz A
    Drug Discov Today Technol; 2016; 21-22():27-34. PubMed ID: 27978984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
    Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
    Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.
    Garralda E; Dienstmann R; Tabernero J
    Am Soc Clin Oncol Educ Book; 2017; 37():210-215. PubMed ID: 28561730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development.
    Ma H; Pilvankar M; Wang J; Giragossian C; Popel AS
    ACS Pharmacol Transl Sci; 2021 Feb; 4(1):213-225. PubMed ID: 33615174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated PK-PD and agent-based modeling in oncology.
    Wang Z; Butner JD; Cristini V; Deisboeck TS
    J Pharmacokinet Pharmacodyn; 2015 Apr; 42(2):179-89. PubMed ID: 25588379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Array of translational systems pharmacodynamic models of anti-cancer drugs.
    Ait-Oudhia S; Mager DE
    J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development.
    Bernard A; Kimko H; Mital D; Poggesi I
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1057-69. PubMed ID: 22632710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current mathematical models for cancer drug discovery.
    Carrara L; Lavezzi SM; Borella E; De Nicolao G; Magni P; Poggesi I
    Expert Opin Drug Discov; 2017 Aug; 12(8):785-799. PubMed ID: 28595492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
    Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in
    Tosca EM; Rocchetti M; Magni P
    Oncotarget; 2021 Jul; 12(14):1434-1441. PubMed ID: 34262653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical models for translational and clinical oncology.
    Gallasch R; Efremova M; Charoentong P; Hackl H; Trajanoski Z
    J Clin Bioinforma; 2013 Nov; 3(1):23. PubMed ID: 24195863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.